Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Concurrent chemoradiotherapy for unresectable thymic carcinoma.

Yen-Yang Chen1, Cheng-Hua Huang, Yeh Tang

  • 1Department of Internal Medicine, Chang Gung Memorial Hospital, Kaohsiung, Taiwan 833, ROC.

Chang Gung Medical Journal
|October 29, 2004
PubMed
Summary

Concurrent chemoradiotherapy shows promise for unresectable thymic carcinoma, offering a 50% response rate and a median survival of 82 months. This approach is effective and warrants further investigation in randomized trials.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Efficacy and safety of a novel oral anti-vasculogenic mimicry agent, CVM-1118, in advanced well-differentiated neuroendocrine tumors: a Phase IIa trial.

British journal of cancer·2026
Same author

A culturally adapted online Mediterranean diet intervention for metabolic dysfunction-associated steatotic liver disease (TIMA): study protocol for a randomized controlled trial.

Trials·2026
Same author

Tackling similarities and differences in global practice guidelines for gastric cancer: a review on the latest Taiwan guidelines with Asia-Pacific, European and US guidelines.

Gastric cancer : official journal of the International Gastric Cancer Association and the Japanese Gastric Cancer Association·2026
Same author

A nomogram for predicting recurrence-free survival in patients with high-risk GIST receiving adjuvant imatinib: A nationwide registry study.

Experimental and therapeutic medicine·2026
Same author

Mediterranean Diet Adherence Is Associated With Reduced Liver Fibrosis Risk in Metabolic Dysfunction-Associated Steatotic Liver Disease.

Journal of gastroenterology and hepatology·2026
Same author

Third-line platinum-based chemotherapy for patients with metastatic pancreatic ductal adenocarcinoma.

Journal of the Formosan Medical Association = Taiwan yi zhi·2026

Area of Science:

  • Medical Oncology
  • Thoracic Surgery
  • Radiation Oncology

Background:

  • Thymic carcinoma is a rare, aggressive anterior mediastinal neoplasm.
  • Complete surgical resection is often unfeasible due to advanced invasion or metastasis.
  • The optimal treatment strategy for unresectable thymic carcinoma remains uncertain.

Purpose of the Study:

  • To evaluate the efficacy of concurrent chemoradiotherapy in patients with unresectable thymic carcinoma.
  • To assess treatment response, survival outcomes, and toxicity in this patient cohort.

Main Methods:

  • Retrospective analysis of 16 patients with unresectable thymic carcinoma treated between 1989 and 2003.
  • Concurrent chemoradiotherapy regimens included cisplatin/5-fluorouracil or doxorubicin/cisplatin/vincristine/cyclophosphamide.

Related Experiment Videos

  • Radiotherapy doses ranged from 34.2 to 70 Gy.

    • Main Results:

    • Overall response rate was 50% (25% complete response, 25% partial response).
    • Median survival was 82 months, with 5-year survival at 67.7%.
    • Common toxicities included Grade I/II vomiting, fatigue, esophagitis; all patients had radiation pneumonitis, with no life-threatening events.

    Conclusions:

    • Concurrent chemoradiotherapy demonstrates encouraging efficacy for unresectable thymic carcinoma.
    • The observed outcomes suggest this treatment modality is a viable option.
    • A randomized trial is recommended to definitively establish the impact of concurrent chemoradiotherapy.